Sio Partners Targets Cancer Treatments and SPACs for GrowthRupert Hargreaves
Sio Partners, the specialist healthcare hedge fund, returned 0.9% net of fees and expenses in January, compared to a loss of -1% for the S&P 500 and a gain of 1% for the MSCI World Healthcare Index. Long investments contributed 12.6%, according to a copy of the firm's letter, which ValueWalk has been able to review, while short positions detracted -10.7% from the performance.
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.